Informações:
Falhas:
ID
12804
Descrição
Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+; ODM derived from: https://clinicaltrials.gov/show/NCT01354457
Link
https://clinicaltrials.gov/show/NCT01354457
Palavras-chave
Versões (1)
- 21/12/2015 21/12/2015 -
Transferido a
21 de dezembro de 2015
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Acute Lymphoblastic Leukemia NCT01354457
Eligibility Acute Lymphoblastic Leukemia NCT01354457
- StudyEvent: Eligibility
Similar models
Eligibility Acute Lymphoblastic Leukemia NCT01354457
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
age
Item
age 18-70 years
boolean
C0001779 (UMLS CUI [1])
b-cell acute leukemia
Item
b-all (oms) with >=20 percent of blasts in bone marrow
boolean
C0279593 (UMLS CUI [1])
cd22+ expression
Item
cd22+ expression >=70 percent of the blast population
boolean
C3815865 (UMLS CUI [1])
all patients who have experienced relapse or treatment failure
Item
all previously treated all patients who have experienced relapse or treatment failure
boolean
C0023449 (UMLS CUI [1])
C0277556 (UMLS CUI [2])
C0277556 (UMLS CUI [2])
at least 15 days since previous treatment
Item
at least 15 days since previous treatment
boolean
C0920425 (UMLS CUI [1,1])
C0332168 (UMLS CUI [1,2])
C0332168 (UMLS CUI [1,2])
ecog performance status
Item
performance status 0 - 2
boolean
C1520224 (UMLS CUI [1])
creatinine clearance
Item
creatinine clearance >= 50 ml/min (cockroft formula).
boolean
C0373595 (UMLS CUI [1])
serum bilirubin
Item
serum bilirubin <= 30 mmol/l
boolean
C1278039 (UMLS CUI [1])
informed consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
t-all
Item
t-all
boolean
C0023493 (UMLS CUI [1])
meningeal involvement
Item
meningeal involvement
boolean
C0948840 (UMLS CUI [1])
cd22 expression
Item
cd22 expression on tumor cells or < 70 percent
boolean
C3815865 (UMLS CUI [1])
hiv positive
Item
hiv positive
boolean
C0019699 (UMLS CUI [1])
Hepatitis
Item
active hepatitis b or c
boolean
C0019196 (UMLS CUI [1,1])
C0019163 (UMLS CUI [1,2])
C0019163 (UMLS CUI [1,2])
active infection
Item
active infection within 7 days of starting treatment
boolean
C0009450 (UMLS CUI [1])
left ventricular ejection fraction
Item
left ventricular ejection fraction < 50 percent.
boolean
C0428772 (UMLS CUI [1])
contra-indication
Item
contra-indication to 90y-dota-hll2
boolean
C1301624 (UMLS CUI [1])
malignancy
Item
previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 5 years
boolean
C0006826 (UMLS CUI [1])
psychological, familial, sociological or geographical condition potentially hampering compliance
Item
any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
boolean
C1321605 (UMLS CUI [1])
C0439801 (UMLS CUI [2])
C0009488 (UMLS CUI [3])
C0439801 (UMLS CUI [2])
C0009488 (UMLS CUI [3])
study subject participation status
Item
participation at the same time in another study in which investigational drugs are used
boolean
C2348568 (UMLS CUI [1])
informed consent denied
Item
absence of written informed consent
boolean
C0021430 (UMLS CUI [1])